S&P Futures
6,002.25 -4.25 (-0.07%) Dow Futures
44,790.00 -36.00 (-0.08%) Nasdaq Futures
20,864.50 -15.75 (-0.08%) Russell 2000 Futures
2,435.60 -15.40 (-0.63%) Crude Oil
69.61 +0.67 (+0.97%) Gold
2,630.70 +12.20 (+0.47%)
Pre-Market:
| Previous Close | 104.28 |
| Open | 103.95 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 103.45 - 104.42 |
| 52 Week Range | 92.35 - 120.92 |
| Volume | |
| Avg. Volume | 1,127,211 |
| Market Cap | 207.004B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 18.07 |
| EPS (TTM) | 5.73 |
| Earnings Date | Jan 31, 2025 |
| Forward Dividend & Yield | 3.78 (3.65%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | 116.16 |
- Zacks Small Cap Research
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Monetary Damages Due from Sanofi/Novartis Litigation Settlement On November 11, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a settlement in the patent litigation brought by Genzyme Corporation, a subsidiary of Sanofi, against Novartis. The litigation included a claim for infringement of U.S. Patent No.
GlobeNewswireNovartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers Basel, November 25, 2024 – Novartis will present d
